Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 97 entries
Sorted by: Best Match Show Resources per page
Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension.

Chonnam medical journal

Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W.
PMID: 23678475
Chonnam Med J. 2013 Apr;49(1):31-7. doi: 10.4068/cmj.2013.49.1.31. Epub 2013 Apr 25.

The effects of statins on insulin resistance and new-onset diabetes are unclear. The purpose of this study was to evaluate the effects of rosuvastatin on insulin resistance and adiponectin in patients with mild to moderate hypertension. In a randomized,...

Cite
Kim W, Hong MJ, Woo JS, et al. Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension. Chonnam Med J. 2013;49(1):31-7doi: 10.4068/cmj.2013.49.1.31.
Kim, W., Hong, M. J., Woo, J. S., Kang, W. Y., Hwang, S. H., & Kim, W. (2013). Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension. Chonnam medical journal, 49(1), 31-7. https://doi.org/10.4068/cmj.2013.49.1.31
Kim, Weon, et al. "Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension." Chonnam medical journal vol. 49,1 (2013): 31-7. doi: https://doi.org/10.4068/cmj.2013.49.1.31
Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W. Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension. Chonnam Med J. 2013 Apr;49(1):31-7. doi: 10.4068/cmj.2013.49.1.31. Epub 2013 Apr 25. PMID: 23678475; PMCID: PMC3651984.
Copy Download .nbib Format: NLM
Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction.

Korean circulation journal

Kim JW, Yun KH, Kim EK, Kim YC, Joe DY, Ko JS, Rhee SJ, Lee EM, Yoo NJ, Kim NH, Oh SK, Jeong JW.
PMID: 24653736
Korean Circ J. 2014 Mar;44(2):76-81. doi: 10.4070/kcj.2014.44.2.76. Epub 2014 Mar 12.

BACKGROUND AND OBJECTIVES: High dose rosuvastatin loading before percutaneous coronary interventions (PCI) reduces the myocardial damage and the incidence of adverse cardiac events in patients with stable angina and acute coronary syndrome. However, no studies are present yet about...

Cite
Kim JW, Yun KH, Kim EK, et al. Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction. Korean Circ J. 2014;44(2):76-81doi: 10.4070/kcj.2014.44.2.76.
Kim, J. W., Yun, K. H., Kim, E. K., Kim, Y. C., Joe, D. Y., Ko, J. S., Rhee, S. J., Lee, E. M., Yoo, N. J., Kim, N. H., Oh, S. K., & Jeong, J. W. (2014). Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction. Korean circulation journal, 44(2), 76-81. https://doi.org/10.4070/kcj.2014.44.2.76
Kim, Ji Won, et al. "Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction." Korean circulation journal vol. 44,2 (2014): 76-81. doi: https://doi.org/10.4070/kcj.2014.44.2.76
Kim JW, Yun KH, Kim EK, Kim YC, Joe DY, Ko JS, Rhee SJ, Lee EM, Yoo NJ, Kim NH, Oh SK, Jeong JW. Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction. Korean Circ J. 2014 Mar;44(2):76-81. doi: 10.4070/kcj.2014.44.2.76. Epub 2014 Mar 12. PMID: 24653736; PMCID: PMC3958612.
Copy Download .nbib Format: NLM
A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman.

Korean journal of family medicine

Ko KD, Kim KK, Baek JO, Suh HS, Hwang IC.
PMID: 29383212
Korean J Fam Med. 2018 Jan;39(1):51-53. doi: 10.4082/kjfm.2018.39.1.51. Epub 2018 Jan 23.

Ichthyosis is a heterogeneous group of hereditary or acquired skin disorders, characterized by increased stratum corneum production. Several systemic diseases and many drugs can occasionally cause acquired ichthyosis. We report a case of statin-induced ichthyosis in which the causality...

Cite
Ko KD, Kim KK, Baek JO, et al. A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman. Korean J Fam Med. 2018;39(1):51-53doi: 10.4082/kjfm.2018.39.1.51.
Ko, K. D., Kim, K. K., Baek, J. O., Suh, H. S., & Hwang, I. C. (2018). A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman. Korean journal of family medicine, 39(1), 51-53. https://doi.org/10.4082/kjfm.2018.39.1.51
Ko, Ki Dong, et al. "A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman." Korean journal of family medicine vol. 39,1 (2018): 51-53. doi: https://doi.org/10.4082/kjfm.2018.39.1.51
Ko KD, Kim KK, Baek JO, Suh HS, Hwang IC. A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman. Korean J Fam Med. 2018 Jan;39(1):51-53. doi: 10.4082/kjfm.2018.39.1.51. Epub 2018 Jan 23. PMID: 29383212; PMCID: PMC5788846.
Copy Download .nbib Format: NLM
Do statins adversely affect the HbA.

Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

Son WD, Teng CL.
PMID: 28503276
Malays Fam Physician. 2017 Apr 30;12(1):39-40. eCollection 2017.

This paper discusses the adverse effect of statins on the HbA

Cite
Son WD, Teng CL. Do statins adversely affect the HbA. Malays Fam Physician. 2017;12(1):39-40
Son, W. D., & Teng, C. L. (2017). Do statins adversely affect the HbA. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia, 12(1), 39-40.
Son, W D, and Teng, C L. "Do statins adversely affect the HbA." Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia vol. 12,1 (2017): 39-40.
Son WD, Teng CL. Do statins adversely affect the HbA. Malays Fam Physician. 2017 Apr 30;12(1):39-40. eCollection 2017. PMID: 28503276; PMCID: PMC5420325.
Copy Download .nbib Format: NLM
Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries.

Korean circulation journal

Sim DS, Jeong MH.
PMID: 29035427
Korean Circ J. 2017 Nov;47(6):811-822. doi: 10.4070/kcj.2017.0027. Epub 2017 Sep 18.

The Korea Acute Myocardial Infarction Registry (KAMIR) is the first nationwide registry that reflects current therapeutic approaches and acute myocardial infarction (AMI) management in Korea. The results of the KAMIR demonstrated different risk factors and responses to medical and...

Cite
Sim DS, Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean Circ J. 2017;47(6):811-822doi: 10.4070/kcj.2017.0027.
Sim, D. S., & Jeong, M. H. (2017). Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean circulation journal, 47(6), 811-822. https://doi.org/10.4070/kcj.2017.0027
Sim, Doo Sun, and Jeong, Myung Ho. "Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries." Korean circulation journal vol. 47,6 (2017): 811-822. doi: https://doi.org/10.4070/kcj.2017.0027
Sim DS, Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries. Korean Circ J. 2017 Nov;47(6):811-822. doi: 10.4070/kcj.2017.0027. Epub 2017 Sep 18. PMID: 29035427; PMCID: PMC5711672.
Copy Download .nbib Format: NLM
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.

Circulation

Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, De Paco Matallana C, Cicero S, Greco E, Singh M, Janga D, Del Mar Gil M, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH.
PMID: 34162218
Circulation. 2021 Aug 31;144(9):670-679. doi: 10.1161/CIRCULATIONAHA.121.053963. Epub 2021 Jun 24.

BACKGROUND: Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a...

Cite
Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021;144(9):670-679doi: 10.1161/CIRCULATIONAHA.121.053963.
Döbert, M., Varouxaki, A. N., Mu, A. C., Syngelaki, A., Ciobanu, A., Akolekar, R., De Paco Matallana, C., Cicero, S., Greco, E., Singh, M., Janga, D., Del Mar Gil, M., Jani, J. C., Bartha, J. L., Maclagan, K., Wright, D., & Nicolaides, K. H. (2021). Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 144(9), 670-679. https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Döbert, Moritz, et al. "Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia." Circulation vol. 144,9 (2021): 670-679. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, De Paco Matallana C, Cicero S, Greco E, Singh M, Janga D, Del Mar Gil M, Jani JC, Bartha JL, Maclagan K, Wright D, Nicolaides KH. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021 Aug 31;144(9):670-679. doi: 10.1161/CIRCULATIONAHA.121.053963. Epub 2021 Jun 24. PMID: 34162218.
Copy Download .nbib Format: NLM
Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.

The Journal of urology

Kramer JJ, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland SJ.
PMID: 34544265
J Urol. 2022 Feb;207(2):417-423. doi: 10.1097/JU.0000000000002199. Epub 2021 Sep 21.

PURPOSE: Benign prostatic hyperplasia (BPH) is a common disease often manifested by lower urinary tract symptoms (LUTS). We previously found statins were associated with modest attenuations in prostate growth over time in REDUCE. We tested whether statins were associated...

Cite
Kramer JJ, Gu L, Moreira D, et al. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol. 2021;207(2):417-423doi: 10.1097/JU.0000000000002199.
Kramer, J. J., Gu, L., Moreira, D., Andriole, G., Csizmadi, I., & Freedland, S. J. (2022). Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. The Journal of urology, 207(2), 417-423. https://doi.org/10.1097/JU.0000000000002199
Kramer, Jordan J, et al. "Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial." The Journal of urology vol. 207,2 (2022): 417-423. doi: https://doi.org/10.1097/JU.0000000000002199
Kramer JJ, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland SJ. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol. 2022 Feb;207(2):417-423. doi: 10.1097/JU.0000000000002199. Epub 2021 Sep 21. PMID: 34544265.
Copy Download .nbib Format: NLM
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.

Circulation

Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M.
PMID: 33438437
Circulation. 2021 Mar 16;143(11):1109-1122. doi: 10.1161/CIRCULATIONAHA.120.049447. Epub 2021 Jan 13.

BACKGROUND: Recent international guidelines have lowered recommended target levels of low-density lipoprotein cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascular events (MACE). However, uncertainty persists whether additional benefit results from achieved LDL-C levels below the...

Cite
Schwartz GG, Gabriel Steg P, Bhatt DL, et al. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021;143(11):1109-1122doi: 10.1161/CIRCULATIONAHA.120.049447.
Schwartz, G. G., Gabriel Steg, P., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Kim, Y. U., Li, Q. H., Manvelian, G., Pordy, R., Sourdille, T., White, H. D., Szarek, M. (2021). Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation, 143(11), 1109-1122. https://doi.org/10.1161/CIRCULATIONAHA.120.049447
Schwartz, Gregory G, et al. "Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial." Circulation vol. 143,11 (2021): 1109-1122. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.049447
Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021 Mar 16;143(11):1109-1122. doi: 10.1161/CIRCULATIONAHA.120.049447. Epub 2021 Jan 13. PMID: 33438437; PMCID: PMC7969166.
Copy Download .nbib Format: NLM
An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia.

Expert review of neurotherapeutics

Dutta S, Rahman S, Ahmad R, Kumar T, Dutta G, Banerjee S, Abubakar AR, Rowaiye AB, Dhingra S, Ravichandiran V, Kumar S, Sharma P, Haque M, Charan J.
PMID: 34756134
Expert Rev Neurother. 2021 Dec;21(12):1455-1472. doi: 10.1080/14737175.2021.2003705. Epub 2021 Nov 29.

INTRODUCTION: Dementia is a progressive neurodegenerative disorder impairing memory and cognition. Alzheimer's Disease, followed by vascular dementia - the most typical form. Risk factors for vascular dementia include diabetes, cardiovascular disease, hyperlipidemia. Lipids' levels are significantly associated with vascular...

Cite
Dutta S, Rahman S, Ahmad R, et al. An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. Expert Rev Neurother. 2021;21(12):1455-1472doi: 10.1080/14737175.2021.2003705.
Dutta, S., Rahman, S., Ahmad, R., Kumar, T., Dutta, G., Banerjee, S., Abubakar, A. R., Rowaiye, A. B., Dhingra, S., Ravichandiran, V., Kumar, S., Sharma, P., Haque, M., & Charan, J. (2021). An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. Expert review of neurotherapeutics, 21(12), 1455-1472. https://doi.org/10.1080/14737175.2021.2003705
Dutta, Siddhartha, et al. "An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia." Expert review of neurotherapeutics vol. 21,12 (2021): 1455-1472. doi: https://doi.org/10.1080/14737175.2021.2003705
Dutta S, Rahman S, Ahmad R, Kumar T, Dutta G, Banerjee S, Abubakar AR, Rowaiye AB, Dhingra S, Ravichandiran V, Kumar S, Sharma P, Haque M, Charan J. An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. Expert Rev Neurother. 2021 Dec;21(12):1455-1472. doi: 10.1080/14737175.2021.2003705. Epub 2021 Nov 29. PMID: 34756134.
Copy Download .nbib Format: NLM
Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients.

The Journal of laryngology and otology

Heward E, Lau AS.
PMID: 31964433
J Laryngol Otol. 2020 Jan 22;1-3. doi: 10.1017/S0022215120000122. Epub 2020 Jan 22.

OBJECTIVE: Epistaxis is a common ENT presentation. The British National Formulary lists epistaxis as a common side effect of atorvastatin. This study aimed to better understand the relationship between epistaxis and atorvastatin use, and determine whether ENT doctors are...

Cite
Heward E, Lau AS. Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients. J Laryngol Otol. 2020;1-3doi: 10.1017/S0022215120000122.
Heward, E., & Lau, A. S. (2020). Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients. The Journal of laryngology and otology, 1-3. https://doi.org/10.1017/S0022215120000122
Heward, E, and Lau, A S. "Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients." The Journal of laryngology and otology vol. (2020): 1-3. doi: https://doi.org/10.1017/S0022215120000122
Heward E, Lau AS. Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients. J Laryngol Otol. 2020 Jan 22;1-3. doi: 10.1017/S0022215120000122. Epub 2020 Jan 22. PMID: 31964433.
Copy Download .nbib Format: NLM
Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015).

Annals of geriatric medicine and research

Kim S, Choi H, Won CW.
PMID: 32743329
Ann Geriatr Med Res. 2020 Jun;24(2):91-98. doi: 10.4235/agmr.20.0028. Epub 2020 Jun 29.

BACKGROUND: This study aimed to identify adverse events and mortality in adults aged 75 years and older who were initially prescribed statins for primary prevention.METHODS: This retrospective study analyzed the data from the National Health Insurance Corporation-Senior Cohort from...

Cite
Kim S, Choi H, Won CW. Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). Ann Geriatr Med Res. 2020;24(2):91-98doi: 10.4235/agmr.20.0028.
Kim, S., Choi, H., & Won, C. W. (2020). Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). Annals of geriatric medicine and research, 24(2), 91-98. https://doi.org/10.4235/agmr.20.0028
Kim, Sunyoung, et al. "Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015)." Annals of geriatric medicine and research vol. 24,2 (2020): 91-98. doi: https://doi.org/10.4235/agmr.20.0028
Kim S, Choi H, Won CW. Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). Ann Geriatr Med Res. 2020 Jun;24(2):91-98. doi: 10.4235/agmr.20.0028. Epub 2020 Jun 29. PMID: 32743329; PMCID: PMC7370796.
Copy Download .nbib Format: NLM
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.

Journal of clinical pharmacy and therapeutics

Shin J, Kim H, Yim HW, Kim JH, Lee S, Kim HS.
PMID: 34668200
J Clin Pharm Ther. 2021 Oct 20; doi: 10.1111/jcpt.13544. Epub 2021 Oct 20.

WHAT IS KNOWN AND OBJECTIVES: Regardless of statin use, which is known to induce hyperglycaemia, comparative studies on the risk of new-onset diabetes mellitus (NODM) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are needed. This...

Cite
Shin J, Kim H, Yim HW, et al. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. J Clin Pharm Ther. 2021;doi: 10.1111/jcpt.13544.
Shin, J., Kim, H., Yim, H. W., Kim, J. H., Lee, S., & Kim, H. S. (2021). Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. Journal of clinical pharmacy and therapeutics, . https://doi.org/10.1111/jcpt.13544
Shin, Juyoung, et al. "Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use." Journal of clinical pharmacy and therapeutics vol. (2021). doi: https://doi.org/10.1111/jcpt.13544
Shin J, Kim H, Yim HW, Kim JH, Lee S, Kim HS. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use. J Clin Pharm Ther. 2021 Oct 20; doi: 10.1111/jcpt.13544. Epub 2021 Oct 20. PMID: 34668200.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 97 entries